Evidence that central 5-hydroxytryptaminergic neurones are involved in the anxiolytic activity of buspirone

M. Carli, C. Prontera, R. Samanin

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

1. A two-compartment exploratory test was used to assess the role of central 5-hydroxytryptaminergic neurones in the anxiolytic activity of buspirone in rats. 2. Buspirone 0.1 mg kg-1, administered subcutaneously 15 min before testing, significantly increased black-white transitions (BWT) in control rats but had no effect in animals injected intracerebroventricularly one week before with 150 μg 5,7-dihydroxytryptamine (in 20 μl). 3. Infusion of buspirone in the median raphe (but not in the dorsal raphe) significantly enhanced BWT, at doses from 1 μg to 10 μg (in 0.5 μl). Buspirone 5 and 10 μg, but not 1 μg, administered in the median raphe, significantly enhanced motor activity of rats during the first 10 min of testing in the activity cages. 4. The effect on BWT of 5 μg buspirone in the median raphe was completely antogonized in animals which had received either 5,7-dihydroxytryptamine intraventricularly, 150 μg (in 20 μl), one week before or an infusion of 0.1 μg (in 0.5 μl) (-)-propranolol in the same area 5 min before. (-)-Propranolol infused in the median raphe did not modify the effect of buspirone on locomotion. 5. Infusion of 5 μg buspirone (in 0.5 μl) in the median raphe significantly enhanced punished responses in a conflict test with no effect on unpunished responding. Buspirone infused in the dorsal raphe had no effect on punished or unpunished responding over a wide dose range. 6. The results indicate that at the relatively low dose used in the present study buspirone produces an anxiolytic effect by acting on central 5-hydroxytryptaminergic neurones. It is likely that activation of 5-hydroxytryptamine(1A)-receptors in the median raphe is involved.

Original languageEnglish
Pages (from-to)829-836
Number of pages8
JournalBritish Journal of Pharmacology
Volume96
Issue number4
Publication statusPublished - 1989

Fingerprint

Buspirone
Anti-Anxiety Agents
Neurons
5,7-Dihydroxytryptamine
Propranolol
Receptor, Serotonin, 5-HT1A
Locomotion
Motor Activity

ASJC Scopus subject areas

  • Pharmacology

Cite this

Evidence that central 5-hydroxytryptaminergic neurones are involved in the anxiolytic activity of buspirone. / Carli, M.; Prontera, C.; Samanin, R.

In: British Journal of Pharmacology, Vol. 96, No. 4, 1989, p. 829-836.

Research output: Contribution to journalArticle

@article{2441768faf4b41c4a9890631ace20c82,
title = "Evidence that central 5-hydroxytryptaminergic neurones are involved in the anxiolytic activity of buspirone",
abstract = "1. A two-compartment exploratory test was used to assess the role of central 5-hydroxytryptaminergic neurones in the anxiolytic activity of buspirone in rats. 2. Buspirone 0.1 mg kg-1, administered subcutaneously 15 min before testing, significantly increased black-white transitions (BWT) in control rats but had no effect in animals injected intracerebroventricularly one week before with 150 μg 5,7-dihydroxytryptamine (in 20 μl). 3. Infusion of buspirone in the median raphe (but not in the dorsal raphe) significantly enhanced BWT, at doses from 1 μg to 10 μg (in 0.5 μl). Buspirone 5 and 10 μg, but not 1 μg, administered in the median raphe, significantly enhanced motor activity of rats during the first 10 min of testing in the activity cages. 4. The effect on BWT of 5 μg buspirone in the median raphe was completely antogonized in animals which had received either 5,7-dihydroxytryptamine intraventricularly, 150 μg (in 20 μl), one week before or an infusion of 0.1 μg (in 0.5 μl) (-)-propranolol in the same area 5 min before. (-)-Propranolol infused in the median raphe did not modify the effect of buspirone on locomotion. 5. Infusion of 5 μg buspirone (in 0.5 μl) in the median raphe significantly enhanced punished responses in a conflict test with no effect on unpunished responding. Buspirone infused in the dorsal raphe had no effect on punished or unpunished responding over a wide dose range. 6. The results indicate that at the relatively low dose used in the present study buspirone produces an anxiolytic effect by acting on central 5-hydroxytryptaminergic neurones. It is likely that activation of 5-hydroxytryptamine(1A)-receptors in the median raphe is involved.",
author = "M. Carli and C. Prontera and R. Samanin",
year = "1989",
language = "English",
volume = "96",
pages = "829--836",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Evidence that central 5-hydroxytryptaminergic neurones are involved in the anxiolytic activity of buspirone

AU - Carli, M.

AU - Prontera, C.

AU - Samanin, R.

PY - 1989

Y1 - 1989

N2 - 1. A two-compartment exploratory test was used to assess the role of central 5-hydroxytryptaminergic neurones in the anxiolytic activity of buspirone in rats. 2. Buspirone 0.1 mg kg-1, administered subcutaneously 15 min before testing, significantly increased black-white transitions (BWT) in control rats but had no effect in animals injected intracerebroventricularly one week before with 150 μg 5,7-dihydroxytryptamine (in 20 μl). 3. Infusion of buspirone in the median raphe (but not in the dorsal raphe) significantly enhanced BWT, at doses from 1 μg to 10 μg (in 0.5 μl). Buspirone 5 and 10 μg, but not 1 μg, administered in the median raphe, significantly enhanced motor activity of rats during the first 10 min of testing in the activity cages. 4. The effect on BWT of 5 μg buspirone in the median raphe was completely antogonized in animals which had received either 5,7-dihydroxytryptamine intraventricularly, 150 μg (in 20 μl), one week before or an infusion of 0.1 μg (in 0.5 μl) (-)-propranolol in the same area 5 min before. (-)-Propranolol infused in the median raphe did not modify the effect of buspirone on locomotion. 5. Infusion of 5 μg buspirone (in 0.5 μl) in the median raphe significantly enhanced punished responses in a conflict test with no effect on unpunished responding. Buspirone infused in the dorsal raphe had no effect on punished or unpunished responding over a wide dose range. 6. The results indicate that at the relatively low dose used in the present study buspirone produces an anxiolytic effect by acting on central 5-hydroxytryptaminergic neurones. It is likely that activation of 5-hydroxytryptamine(1A)-receptors in the median raphe is involved.

AB - 1. A two-compartment exploratory test was used to assess the role of central 5-hydroxytryptaminergic neurones in the anxiolytic activity of buspirone in rats. 2. Buspirone 0.1 mg kg-1, administered subcutaneously 15 min before testing, significantly increased black-white transitions (BWT) in control rats but had no effect in animals injected intracerebroventricularly one week before with 150 μg 5,7-dihydroxytryptamine (in 20 μl). 3. Infusion of buspirone in the median raphe (but not in the dorsal raphe) significantly enhanced BWT, at doses from 1 μg to 10 μg (in 0.5 μl). Buspirone 5 and 10 μg, but not 1 μg, administered in the median raphe, significantly enhanced motor activity of rats during the first 10 min of testing in the activity cages. 4. The effect on BWT of 5 μg buspirone in the median raphe was completely antogonized in animals which had received either 5,7-dihydroxytryptamine intraventricularly, 150 μg (in 20 μl), one week before or an infusion of 0.1 μg (in 0.5 μl) (-)-propranolol in the same area 5 min before. (-)-Propranolol infused in the median raphe did not modify the effect of buspirone on locomotion. 5. Infusion of 5 μg buspirone (in 0.5 μl) in the median raphe significantly enhanced punished responses in a conflict test with no effect on unpunished responding. Buspirone infused in the dorsal raphe had no effect on punished or unpunished responding over a wide dose range. 6. The results indicate that at the relatively low dose used in the present study buspirone produces an anxiolytic effect by acting on central 5-hydroxytryptaminergic neurones. It is likely that activation of 5-hydroxytryptamine(1A)-receptors in the median raphe is involved.

UR - http://www.scopus.com/inward/record.url?scp=0024514567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024514567&partnerID=8YFLogxK

M3 - Article

VL - 96

SP - 829

EP - 836

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 4

ER -